Dashboard
Company has a low Debt to Equity ratio (avg) at 0.01 times
Poor long term growth as Net Sales has grown by an annual rate of 1.51% and Operating profit at 1.69% over the last 5 years
With a growth in Net Profit of 158.31%, the company declared Very Positive results in Mar 26
Stock is technically in a Mildly Bullish range
With ROE of 8.1, it has a Very Expensive valuation with a 1.9 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
INR 3,813 Cr (Small Cap)
25.00
42
0.80%
-0.01
6.62%
2.04
Total Returns (Price + Dividend) 
Latest dividend: 1.001474728515887 per share ex-dividend date: Feb-17-2026
Risk Adjusted Returns v/s 
Returns Beta
News

Broad-Based Technical Strength Lifts IOL Chemicals & Pharmaceuticals Ltd to 52-Week High of Rs 126.87
With a decisive surge to Rs 126.87 on 21 May 2026, IOL Chemicals & Pharmaceuticals Ltd has reached a fresh 52-week high, marking a remarkable 42.38% gain over the past year against the Sensex’s decline of 7.94%. This rally is underpinned by a confluence of bullish technical indicators and sustained price momentum, setting the stock apart in a challenging market environment.
Read More
IOL Chemicals & Pharmaceuticals Ltd is Rated Hold
IOL Chemicals & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 28 Apr 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 21 May 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.
Read More
IOL Chemicals & Pharmaceuticals Ltd Reports Very Positive Quarterly Financial Performance
IOL Chemicals & Pharmaceuticals Ltd has delivered a standout quarterly performance for March 2026, marking a significant improvement in its financial trend and market returns. The company’s latest results reveal record-breaking revenue and profit metrics, driving an upgrade in its Mojo Grade from Sell to Hold and signalling renewed investor confidence amid a challenging sector backdrop.
Read More Announcements 
Communication To Shareholders Relating To Unclaimed Dividend
11-Jun-2026 | Source : BSEIntimation regarding communication to shareholders relating to unclaimed dividend
Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015
10-Jun-2026 | Source : BSEDisclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
28-May-2026 | Source : BSEEarning call transcript
Corporate Actions 
No Upcoming Board Meetings
IOL Chemicals & Pharmaceuticals Ltd has declared 50% dividend, ex-date: 17 Feb 26
IOL Chemicals & Pharmaceuticals Ltd has announced 2:10 stock split, ex-date: 11 Mar 25
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 6 Schemes (0.02%)
Held by 53 FIIs (1.72%)
Maya Devi Polycot Limited (21.79%)
Synthorix Trading Limited (3.81%)
31.03%
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
QoQ Growth in quarter ended Mar 2026 is 6.73% vs 2.27% in Dec 2025
QoQ Growth in quarter ended Mar 2026 is 158.31% vs -31.33% in Dec 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 8.86% vs -7.25% in Sep 2024
Growth in half year ended Sep 2025 is 30.09% vs -41.34% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 9.55% vs -4.75% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 21.29% vs -34.79% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 11.54% vs -2.51% in Mar 2025
YoY Growth in year ended Mar 2026 is 36.18% vs -24.82% in Mar 2025